Angiotech Pharmaceuticals ( ANPI) shares lifted Tuesday when the company said it met analysts' expectations for first-quarter earnings despite falling short on revenue.

On a GAAP basis, the Vancouver-based company earned $8 million, or 9 cents a share, in the quarter vs. $19.2 million, or 23 cents share, a year earlier. According to the company, the decrease was primarily due to lower royalty revenue from sales of Boston Scientific's ( BSX) drug-eluting coronary stents.

Excluding certain charges, Angiotech earned 16 cents a share, in line with analysts' estimates. Minus certain litigation expenses, the company earned 19 cents a share. Shares closed Tuesday up 12 cents, or 0.8%, at $14.82.

Revenue for the quarter came in at $41.9 million, including $39.4 million in royalties from Boston's stents. Analysts were expecting Angiotech's top line to reach $49.25 million. Boston has a licensing agreement with Angiotech to use the drug paclitaxel to coat its stents, which are heart devices used to prop open vessels cleared of plaque. The drug is used to prevent vessel reclogging.

Separately, Angiotech has closed its acquisition of American Medical Instruments Holdings for $787.9 million in cash, plus an acquisition cost of $8.2 million. Angiotech will begin reporting American Medical Instruments results as a part of its overall results starting with the second quarter.

More from Stocks

The Stock Market Has Every Reason to See a Fresh Rally

The Stock Market Has Every Reason to See a Fresh Rally

3 Simple Tips on Investing From TheStreet's Jim Cramer

3 Simple Tips on Investing From TheStreet's Jim Cramer

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Tesla's Supercharger Network Is Booming -- Here's Why That's a Concern

Tesla's Supercharger Network Is Booming -- Here's Why That's a Concern

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly